Department of Internal Medicine I, Fetscherstr. 74, 01307 Dresden, Germany.
Anticancer Res. 2012 Feb;32(2):421-5.
Associations between polymorphisms of the epidermal growth factor receptor (EGFR) and overall survival in patients with advanced carcinoma of the head and neck (HNSCC) receiving cetuximab based palliative treatment, were evaluated.
HNSCC patients (n=48) received cetuximab +/- chemotherapy. Samples for DNA extraction and clinical data were collected prospectively. Genotyping of four EGF(R) polymorphisms was performed using PCR-based restriction fragment length polymorphism (RFLP).
The median overall survival was 10.6 months. The EGFR-R497K polymorphism was significantly associated with overall survival. The presence of at least one K-allele was associated with shorter overall survival. The median survival in these patients was 6.7 months compared to 13.3 months in the patients homozygous for the wild type allele EGFR-497R (p=0.009). Addition of chemotherapy to cetuximab, age and EGFR-R497K polymorphism were independent predictors of overall survival. Multivariate analysis revealed a hazard ratio (HR) for patients with at least one EGFR-497K allele of 3.03 when compared with EGFR-497R homozygous patients (p=0.045).
The EGFR-R497K polymorphism is a potential predictor for overall survival in HNSCC patients treated with cetuximab based therapy in the palliative setting.
评估表皮生长因子受体（EGFR）多态性与接受基于西妥昔单抗的姑息性治疗的晚期头颈部癌（HNSCC）患者总生存期之间的关系。
HNSCC 患者（n=48）接受西妥昔单抗 +/- 化疗。前瞻性收集用于 DNA 提取和临床数据的样本。使用基于 PCR 的限制性片段长度多态性（RFLP）对四个 EGF（R）多态性进行基因分型。
中位总生存期为 10.6 个月。EGFR-R497K 多态性与总生存期显著相关。至少存在一个 K-等位基因与总生存期较短相关。这些患者的中位生存时间为 6.7 个月，而 EGFR-497R 纯合野生型患者的中位生存时间为 13.3 个月（p=0.009）。西妥昔单抗联合化疗、年龄和 EGFR-R497K 多态性是总生存期的独立预测因素。多变量分析显示，至少存在一个 EGFR-497K 等位基因的患者的危险比（HR）为 3.03，与 EGFR-497R 纯合患者相比（p=0.045）。
在姑息治疗中接受基于西妥昔单抗的治疗的 HNSCC 患者中，EGFR-R497K 多态性是总生存期的潜在预测因子。
